Sustained Virological Response and Baseline Predictors in HIV-HCV Coinfected Patients Retreated with Pegylated Interferon and Ribavirin after Failing a Previous Interferon-Based Therapy: Systematic Review and Meta-Analysis

REFERENCES

• Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: A close look at the role for direct-acting antivirals. Gastroenterology. 2012;142: 1324–1334.
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV coinfection. Antiviral Res. 2010;85: 303–315.
   PubMed Web of Science ®Google Scholar
• Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther. 2010;31:502–508.
   PubMed Web of Science ®Google Scholar
• Soriano V, Poveda E, Vispo E, Labarga P, RalIón N, Barreiro P. Pharmacogenetics of hepatitis C. J Antimicrob Chemother. 2012;67:523–529.
   PubMed Web of Science ®Google Scholar
• Vogel M, Rockstroch JK. The treatment of chronic hepatitis C virus infection in HIV co-infection. Eur J Med Res. 2009;14:507–515.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J HepatoL 2011;55:245–264.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis. 2013;207(Suppl 1):526–32.
   Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepati-tis C: A randomised trial. Lancet. 2001;358:958–965.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
   PubMed Web of Science ®Google Scholar
• Lorio A, Marchesini E, Awad T, Gluud LL. Antiviral treat-ment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database Syst Rev. 2010;CD004888.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coin-fected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–413.
   PubMed Web of Science ®Google Scholar
• Angeli E, Mainini A, Meraviglia P, et al. Eligibility and fea-sibility of the treatment of chronic hepatitis C in a cohort of Italian HIV-positive patients at a single HIV reference center. AIDS Patient Care STDS. 2011;25:295–301.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonran-domized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/nosgen.doc. Accessed October 30,2012.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.
   Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Harbord RM, Egger M, Sterne JA. A modified test for small study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:3443–3457.
   PubMed Web of Science ®Google Scholar
• Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–680.
   PubMed Web of Science ®Google Scholar
• Myers RP, Benhamou Y, Bochet M, Thibault V,Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75–79.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol. 2007;38:32–38.
   PubMed Web of Science ®Google Scholar
• Crespo M, Mira JA, Pineda JA, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Che-mother. 2008;62:793–796.
   PubMed Web of Science ®Google Scholar
• Labarga P, Vispo E, Barreiro P, et al. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C virus coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr. 2010;53:64–68.
   Web of Science ®Google Scholar
• Vachon ML, Factor SH, Branch AD, et al. Insulin resis-tance predicts re-treatment failure in an efficacy study of peginterferon-a-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol. 201154: 41–47.
   Google Scholar
• Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginter-feron alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015-1023.
   Google Scholar
• Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfe/ribevirin therapy. Gastroenterology. 2009;136:1618–1628.
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA. 2004;292:2839–2848.
   PubMed Web of Science ®Google Scholar
• Loko MA, Bani-Sadr F, Winnock M, et al. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV coinfected patients. J Viral Hepat. 2011;18:307–314.
   PubMed Web of Science ®Google Scholar
• Medrano J, Neukam K, Rallón N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coin-fected with hepatitis C virus and HIV. Clin Infect Dis. 2010;51:1209–1216.
   PubMed Web of Science ®Google Scholar
• Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol. 2012;56:788–794.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon {alpha}2a plus ribavirin ver-sus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009;63:1256–1263.
   PubMed Web of Science ®Google Scholar
• Laguno M, Cifuentes C, Murillas J, et al Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22–31.
   PubMed Web of Science ®Google Scholar
• Berenguer J, von Wichmann MA, Quereda C, et al. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. J Antimicrob Chemother. 2011;66:2843–2849.
   PubMed Web of Science ®Google Scholar
• Rohrbach J, Robinson N, Harcourt G, et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut. 2010;59:1252–1258.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA. 2012;308:387–402.
   PubMed Web of Science ®Google Scholar
• Avidan NU, Goldstein D, Rozenberg L, et al. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV co-infected patients as a function of base-line CD4+ T cell counts. J Acquir Immune Defic Synd. 2009;52:452–458.
   PubMed Web of Science ®Google Scholar
• Egger M, Schneider M, Davey Smith G. Spurious preci-sion? Meta-analysis of observational studies. Br Med J. 1998;316:140–144.
   PubMed Web of Science ®Google Scholar
• Labarge P, Barreiro P, Mira JA, et al. Impact of IL28B poly-morphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonre-sponse or relapse. AIDS. 2011;25:1131–1133.
   PubMed Web of Science ®Google Scholar